Biovotion and the University of Applied Science Western Switzerland (HES-SO) are to cooperate on the development and implementation of ‘COMPASS’ – Continuous Multi-variate monitoring of patients affected by COPD. This is made possible by the financing of Swiss KTI/CTI. The two groups will bring together extensive expertise and knowledge in high quality wearable monitoring, multivariate data analyses and mHealth eco systems. Biovotion holds internationally recognised expertise and technology in wearable monitoring, supported with an extensive publication track record and IP portfolio. The HES-SO team has extensive international experience on Gestational Diabetes, Diabetes Type 1 and Diabetes Type 2 that was established within the G-DEMANDE and MONDAINE national projects and with the COMMODITY2 European FP7 project.
COMPASS aims to define and create a Personal Health System (PHS) to monitor the physiological parameters of patients affected by e.g. Chronic Obstructive Pulmonary Disease (COPD) and associated chronic illnesses, and predict the physiological state as a support to the decisions taken by medical doctors. COMPASS will achieve this by combining the usage of the state-of-the art Biovotion multi-parametric sensors, pervasive health, interoperability technology, and machine learning techniques. COMPASS will deal with several challenges related to the use of multi-sensor solutions developed by Biovotion, namely: